BTIG Research restated their buy rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) in a report issued on Monday,Benzinga reports. BTIG Research currently has a $30.00 price objective on the stock.
A number of other equities research analysts also recently issued reports on MLTX. Oppenheimer increased their price target on MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. UBS Group set a $24.00 target price on MoonLake Immunotherapeutics in a research report on Friday, January 9th. Needham & Company LLC increased their target price on MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. HC Wainwright raised their price target on MoonLake Immunotherapeutics from $32.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Zacks Research raised MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Nine investment analysts have rated the stock with a Buy rating, four have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $23.08.
Read Our Latest Analysis on MLTX
MoonLake Immunotherapeutics Stock Performance
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported ($0.92) EPS for the quarter, hitting the consensus estimate of ($0.92). During the same quarter in the prior year, the firm earned ($0.72) EPS. Analysts anticipate that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in MLTX. Geode Capital Management LLC lifted its stake in MoonLake Immunotherapeutics by 0.9% during the second quarter. Geode Capital Management LLC now owns 59,553 shares of the company’s stock worth $2,809,000 after purchasing an additional 559 shares during the last quarter. Squarepoint Ops LLC raised its holdings in shares of MoonLake Immunotherapeutics by 3.7% during the 2nd quarter. Squarepoint Ops LLC now owns 17,571 shares of the company’s stock worth $829,000 after buying an additional 629 shares in the last quarter. Axiom Investors LLC DE raised its holdings in shares of MoonLake Immunotherapeutics by 3.2% during the 4th quarter. Axiom Investors LLC DE now owns 25,998 shares of the company’s stock worth $343,000 after buying an additional 818 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of MoonLake Immunotherapeutics by 45.4% during the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock worth $45,000 after buying an additional 1,069 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its position in shares of MoonLake Immunotherapeutics by 18.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock worth $52,000 after buying an additional 1,158 shares during the last quarter. 93.85% of the stock is currently owned by institutional investors and hedge funds.
MoonLake Immunotherapeutics News Roundup
Here are the key news stories impacting MoonLake Immunotherapeutics this week:
- Positive Sentiment: BTIG reaffirmed its Buy rating on MoonLake, keeping institutional support that can attract momentum investors. BTIG Research Reaffirms Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)
- Positive Sentiment: H.C. Wainwright reiterated a Buy on MLTX and continues to use a $40 price target, reinforcing a favorable sell‑side view and a high upside reference point for investors. H.C. Wainwright Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)
- Positive Sentiment: MLTX has drawn retail attention from buyout speculation and release of positive skin‑condition trial data — a near‑term catalyst that likely lifted volume and interest even as volatility increased. MLTX stock garners retail attention on buyout speculation, positive skin condition trial data
- Neutral Sentiment: H.C. Wainwright published quarterly EPS forecasts for 2027 (Q1–Q4) showing continued per‑share losses (e.g., quarterly EPS guides around -$0.70 to -$0.91) while maintaining its Buy stance — useful for modeling near‑term cash burn but not a rating change. HC Wainwright estimates for MoonLake Immunotherapeutics (MarketBeat)
- Neutral Sentiment: MarketWatch’s cash‑flow/financials page provides the company’s liquidity metrics and financials that investors should review — MoonLake shows ample current/quick ratios and modest leverage, which may support runway. MoonLake Immunotherapeutics cash flow (MarketWatch)
- Negative Sentiment: MoonLake reported continuing GAAP losses (recent quarter EPS ~ -$0.92, matching estimates but worse year‑over‑year) and the street expects full‑year negative EPS — a reminder that the company is not yet profitable and remains dependent on funding or positive clinical outcomes. MoonLake financial summary and analyst consensus (MarketBeat)
MoonLake Immunotherapeutics Company Profile
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Recommended Stories
Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
